Other single compounds

Version vom 18. Juni 2020, 11:59 Uhr

Ivermectin
32330482 ä. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors responses
32251768 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
32283237 ä. Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?

• on ivermectin

32322397 2020. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance

Icatibant bradykinin antagonist
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Macrolide antibiotics
32249257 2020. Macrolide treatment for COVID-19: Will this be the way forward?

Teicoplanin
32179150 ä. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?

Doxycycline
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19

Metronidazole retarget
32259129 2020. Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Chlorpromazine retarget

• paper

Lauric acid nat. compd.

• call for trial

Nicotine nat. toxin

• france

32353120 ä. Does Cigarette Smoking Protect Against SARS-CoV-2 Infection?
32242236 ä. COVID-19 and Smoking

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Various Leads

• 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
• paper in nature

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?

PDE5 Inhibitors
32272196 2020. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19

Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

Camostat mesilate
32347443 ä. Camostat mesilate therapy for COVID-19

Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists

Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases

Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?

Resiniferatoxin
32292906 2020. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review

TRPV1 target
C7147214 ä. Potential TRPV1 blockade to treat severe lung dysfunction in COVID-19 infection

Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?

Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?

Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19

Dapsone
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
32339778 ä. Dapsone and Doxycycline could be potential treatment modalities for COVID-19

Colchicine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19

Dextmetrorphan

• dextrometorphan (antitussive compd)

Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

Nitazoxaide
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management

Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Cyclophilin A inhibitors
32347055 2020. Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors

Cyclosporin A
32354685 ä. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia